Duration of diabetes was inversely correlated with age-at-diagnosis (ρ=-0.13). However, as backward stepwise regression was used to test which covariates were required when testing for associations with autoantibody positivity, GADA and IA-2A positivity were both associated with an older age-atdiagnosis as well as a longer duration of disease. The effects attributable to both covariates (and also to sex with GADA) were accounted for in the models testing for genetic associations, (Methods) to ensure the associations obtained with autoantibody positivity were due to genotype. This can be illustrated by comparison of autoantibody positivity by age-at-diagnosis in those cases with the shortest duration of disease, to cases with the longest duration of disease. Within the cases having diabetes for ≤ 2yrs, GADA positivity was 53% in cases with an age-at-diagnosis of ≤ 4 yrs, 57% in cases diagnosed between 5-7 years of age, 69% in those diagnosed between 8-11 years and 70% in those diagnosed between 12-16 years of age. So there was, as expected, a clear trend, that in the cases with the shortest duration of diabetes, GADA positivity was associated with an older age-at-diagnosis. A similar trend was also seen with IA-2A positivity, with 59% of cases diagnosis at ≤ 4 yrs positive for IA-2A compared to 71% of those diagnosed between 12-16 years.
as dependent variable and genotype (or allele) as independent variable was used to test for association with type 1 diabetes. Note, geographical region was included as a confounder to account for variation in disease incidence and allele/genotype frequency across Great Britain (refer to methods of main text). A genotype effects model (which does not assume a specific mode of inheritance) was compared to a multiplicative allelic effects model. The multiplicative model, as is well known, was not an appropriate approximation (P < 7 x 10 -20 ) (10; 11).
HLA-DQB1 and HLA-DRB1 genotypes were both strongly associated with type 1 diabetes (P = 0; Supplementary Table 1 and 2), further more, they had convincing independent effects on diabetes risk (P = 2.91x10 -240 , for addition of HLA-DQB1 genotypes to HLA-DRB1 genotypes; P = 1.28x10 -240 , for addition of HLA-DRB1 genotypes to HLA-DQB1 genotypes). Unexpectedly, a joint model including both HLA-DRB1 and HLA-DQB1, showed that the HLA-DQB1*0302/0302 genotype was more strongly associated with type 1 diabetes than HLA-DQB1*02/0302 (Supplementary Table 1 ). In contrast, the HLA-DRB1*03/04 genotypes were the most associated with type 1 diabetes after conditioning on HLA-DQB1 (08/0401 had a larger OR but the 95% CIs overlapped those for 03/04 and this merely reflects the uncertainty in the effect estimate of the 08/0401 genotype as it is rare). Interestingly, the HLA-DRB1*03/03 genotype which has an unconditional OR (4.57 [3.53 -5 .92]; Supplementary Table 2) similar to HLA-DRB1*0401/0401 .76]; Supplementary Table 2), following conditioning on HLA-DQB1, the susceptibility is significantly reduced with the 95% CI overlapping 1.00. Similarly, the effects of HLA-DRB1*07/09, and *03/11 were reduced, while *03/13 is increased after conditioning on HLA-DQB1.
Effects of duration of diabetes on genetic associations with autoantibody positivity
As most cases were tested for autoantibodies after diagnosis, autoantibody positivity would be less than had all cases been tested for autoantibodies at time of diagnosis; we estimate the false negative rate to be less than 20%. This effect of duration on autoantibody positivity has been accounted for in the statistical analysis by including duration as a covariate in the regression models. Here we illustrate this with reference to the HLA-DRB1*03/04 genotype.
First consider whether or not HLA-DRB1*03/04 is associated with GADA positivity. This can be tested in a logistic regression model, using GADA positivity as the outcome variable and HLA-DRB1*03/04 genotype as independent variable. However, GADA is associated with increasing age-at-diagnosis, and HLA-DRB1*03/04 is also associated with age-at-diagnosis, i.e. age-at-diagnosis is a confounder to be included in the model. GADA positivity has a sex bias (more females are GADA positive than males) so sex is included as a covariate. Using a likelihood ratio test, this model (GADA ~ age-at-diagnosis + sex + DR3/4) could be compared to a model without DR3/4, to determine whether or not DR3/4 is associated with GADA positivity. However, with this test, association of genotype with decline in GADA positivity with diabetes duration, could be detected but interpreted as association of GADA positivity with HLA-DRB1*03/04 genotype. Therefore, to account for decline in GADA positivity with diabetes duration, duration was included as a covariate. No evidence of association of GADA positivity with HLA-DRB1*03/04 genotype was obtained, P = 0.33. As the duration variable was included, decline in autoantibody positivity with disease duration was not tested.
Association of the HLA-DRB1*03/04 genotype with decline in GADA positivity with increasing duration of disease can be tested. We do not have the appropriate study design for this and so the study (across individuals) does not have much statistical power to detect this, but we can apply the test. Using an interaction term in the logistic regression model with GADA positivity as the outcome variable, the independent variables are then HLA-DRB1*03/04 genotype, age-at-diagnosis, sex, duration of disease, and the interaction of HLA-DRB1*03/04 with duration. This interaction term allows us to test the genotype dependence of decline in GADA positivity with duration of disease by comparing this model to a model without the interaction term using a likelihood ratio test. This was not significant, P = 0.15. So there was no association of genotype with decline in GADA positivity in our cohort with a median disease duration of 5 years.
Note however, whether or not there is a genotype dependence of decline in autoantibody positivity with duration of disease a priori is unknown, so for all tests the duration variable was included to ensure we are testing association of GADA positivity with genotype without being confounded by decline in GADA positivity with diabetes duration.
Using the same methods, there was no evidence of a HLA-DRB1*03/04 genotype dependence on decline in IA-2A positivity with duration of diabetes, P = 0.08. Furthermore, HLA-DRB1*03/04 was not associated with IA-2A positivity P=0.92. 
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